Autonomix Medical, Inc. 8-K

What Happened
Autonomix Medical, Inc. (AMIX) announced in an 8-K that Nasdaq's Listing Qualifications staff sent a deficiency letter after the company's common stock had closed below the $1.00 minimum bid price for 30 consecutive business days under Nasdaq Listing Rule 5550(a)(2). That deficiency did not trigger immediate delisting. On July 9, 2026, Nasdaq notified the company it had regained compliance because the stock’s closing bid price was at or above $1.00 for 10 consecutive business days from June 24, 2026 through July 8, 2026; the staff indicated the matter is closed.

Key Details

• Nasdaq rule cited: Listing Rule 5550(a)(2) (minimum $1.00 bid price requirement).
• Deficiency period: stock closed below $1.00 for the prior 30 consecutive business days (per initial letter).
• Cure period: regained compliance with 10 consecutive business days at or above $1.00 from June 24, 2026 to July 8, 2026.
• Nasdaq notified the company on July 9, 2026 that the matter is closed; no immediate delisting occurred.

Why It Matters
This resolves a short-term listing risk: regaining compliance keeps Autonomix Medical’s common stock listed on the Nasdaq Capital Market and avoids the immediate start of a delisting process tied to the bid-price rule. For investors, the company remains tradable on Nasdaq and will continue to be monitored for future compliance with Nasdaq listing standards.